Skip to main content

Prolexys and Ariadne to Integrate Software, Database

NEW YORK, Nov. 16 (GenomeWeb News) - Ariadne Genomics and Prolexys Pharmaceuticals will pair their pathway-analysis tools to target the pharmaceutical research market, the companies said today

 

Under the terms of the agreement, Prolexys' Human Interactome Database, a collection of experimentally verified human protein-protein interactions, will be integrated with Ariadne's PathwayStudio and PathwayExpert pathway-analysis software.


The Prolexys database will be available from Ariadne Genomics for an additional fee to its commercial customers, Prolexys and Ariadne said.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.